{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-012031","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.947445+00:00","generated_at":"2026-05-31T04:22:11.408437+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dermata raises $3.5M gross in private placement; expects cash runway into Q2 2025","bullets":["Gross proceeds $3.5M from 1,912,569 shares/pre-funded warrants + Series A & B warrants at $1.83/unit.","Net proceeds ~$3.0M after placement agent fees; H.C. Wainwright acted as exclusive agent.","Series A warrants (5.5 yr term) and Series B warrants (18 mo term) each exercisable at $1.58/share.","Including prior raises, total $7.8M gross since May 2024; operations funded into Q2 2025.","Proceeds for general corporate purposes including R&D, clinical trials, and licensing."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-012031","json":"https://secwatch.observer/filing/0001654954-24-012031.json","markdown":"https://secwatch.observer/filing/0001654954-24-012031.md","text":"https://secwatch.observer/filing/0001654954-24-012031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424012031/0001654954-24-012031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424012031/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:22:11.408437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}